News | Artificial Intelligence | May 16, 2018

Matrix Analytics Announces Company Rebrand to Eon

Rebranded company will bring optimized artificial intelligence and machine learning resources to conditions beyond lung cancer

Matrix Analytics Announces Company Rebrand to Eon

May 16, 2018 – Denver-based Matrix Analytics announced the company's rebrand to Eon. The rebrand marks the expansion of Eon's offerings beyond LungDirect to a suite of software solutions that will help improve the treatment of complex conditions of any kind. LungDirect, which will be rebranded to EonDirect, is the first and only cloud-based software application for lung cancer screening and incidental nodule management that integrates seamlessly with hospital electronic medical records (EMRs), according to Eon.

Eon provides solutions that use proprietary artificial intelligence and machine learning to optimize diagnoses and treatment efficiency for any condition that requires complex patient management. The company's flagship product, EonDirect, streamlines data to ensure healthcare providers receive the right data at the right time to provide the most effective care for their patients. The company's first expansions will include management of patients with pancreatic, thyroid, liver and renal diseases.

Matrix Analytics was founded in 2015 by interventional pulmonologist Akrum ("Aki") Alzubaidi to address the prevalence of delayed or missed lung cancer diagnoses due to antiquated, inefficient hospital software systems. Leveraging his programming background, Alzubaidi developed LungDirect to better detect and diagnose pulmonary nodules, or spots on the lungs. The technology improved early-stage lung cancer detection at the hospital where Alzubaidi practiced from 23 percent to nearly 50 percent.

Since its founding, the company has largely grown through personal investment by its leaders, but Eon has also raised nearly $2 million in investments, with commitments for an additional $2 million by the end of May 2018. Eon's current advisors include:

  • Mark Cuban, entrepreneur, Dallas Mavericks owner and "Shark Tank" host;
  • George Conrades, IBM executive veteran, CEO of Akamai, board member for Harley Davidson and Oracle;
  • Kevin Hutchinson, entrepreneur, developer of Surescripts, MedicaLogic and Medscape, and CEO of MyTaskit;
  • Joseph Cicenia, M.D., pulmonologist at Cleveland Clinic; and
  • Zach and Chancy Love, private investors.

"EonDirect has added tremendous value to our hospital and is a great investment. In addition to being affordable, their technology has significantly reduced the amount of time our staff spends on administrative tasks and improved how we screen and treat our lung cancer patients," said Scott Skibo, M.D., pulmonologist at Haywood Regional Medical Center. "It is refreshing to work with a company that delivers on its promise and provides truly great customer service."

EonDirect is also being used in the Patient-Centered Outcomes Research Institute's (PCORI) "The Watch the Spot Trial" and is a Certified Software Partner of the American College of Radiology's Lung Cancer Screening Registry.

For more information: www.eonhealth.com

 

Related Content

iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
CHI Franciscan Launches Washington State's First AI-Powered Hospital Mission Control Center
News | Artificial Intelligence | October 08, 2018
CHI Franciscan Health and GE Healthcare have joined forces to implement a NASA-style "Mission Control" command center...
X-ray Mammography Adoption to Skyrocket for Breast Cancer Detection
News | Mammography | October 08, 2018
Highly populated countries have traditionally been slow adopters of non-conventional business models, but a new Frost...
Body Vision Medical Announces Release of LungVision
Technology | Lung Cancer | October 05, 2018
Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its...
Leica Biosystems Launches MammoPort Specimen Containment and Transport System
Technology | Breast Biopsy Systems | October 03, 2018
Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system...
Adherence to Annual Lung Cancer Screening Needs Improvement
News | Lung Cancer | October 03, 2018
A study of adherence to annual low-dose computed tomography (LDCT) screening within the Veteran Health Administration...
News | PACS Accessories | October 01, 2018
M*Modal announced that several large U.S. health systems have adopted its cloud-based artificial intelligence (AI)...